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为是 NAFLD 的有效疗法，多个临床研究证实运动对减肥、减轻 NAFLD 肝内的
TG 含量有确切的疗效。厦门糖尿病研究所所做的强化运动治疗 NAFLD 的临床
研究也显示，强化运动可以减轻患者的体重、降低肝内的 TG。但运动治疗脂肪
肝的机制还不太明了，有待于揭示。我们采用了基于核磁共振的代谢组学检测了
运动 6 个月后患者尿样的代谢组，结合多元数据分析发现：经过 6 个月的强化运
动后患者尿液中与肠道菌群代谢相关的代谢物，如 TMAO， hippurate 发生了的
变化，提示强化运动治疗脂肪肝的机制与运动后肠道菌群的改变有关。 
第二部分  尽管 NAFLD 在世界范围内流行，但是目前还没有安全有效的治
疗性药物。我们发现多种含有中药大黄的复方可以改善 NAFLD 的症状，降低患
者血浆中的 TG 含量。我们推测，大黄可能对 NAFLD 具有治疗作用。在第二部
分中，我们首先观察大黄对高脂诱导的肝脂肪变性是否有效。发现低剂量大黄治
疗可以减轻肝内脂肪变性，降低肝的 TG 含量。进一步的 qTR-PCR 分析显示低
剂量大黄可以调节脂肪酸合成相关的基因，以及 TG 合成基因的 mRNA 的表达。
进一步的 Western-blot 结果显示，低剂量大黄可以增加 AMPK、ACC 的磷酸化
水平。因此我们认为低剂量大黄缓解高脂诱导的肝脂肪变性机制之一是通过激活
AMPK 而实现的。 
   第三部分  我们提出了一种新的多元数据分析方法 mOPLS-DA。使用该方法
可以选择最相关的特征基因进行三类疾病分类和预测。我们先后利用多个数据和





















Nonalcoholic fatty liver disease (NAFLD) has been widely popular in Europe, United States 
and China. Exercise is considered to be an effective for NAFLD. Several clinical studies 
showed that exercise decreased body weight, reduced the liver TG content in NAFLD. The 
clinical study performed by Xiamen diabetes institute also showed that intensive exercise 
reduced body weight and TG content in the livers in NAFLD. But the mechanisms underlying 
exercise for NAFLD are remained to unravel. We collected the urine from the NAFLD six 
months after intensive exercise and performed metabonomic analysis on it by nuclear 
magnetic resonance (NMR). Multivariate data analysis showed that urine metabolites related 
to co-metabolism between host and gut flora, such as TMAO, hippurate changed significantly 
after six months of intensive exercise, which indicating that the mechanisms of exercise for 
NAFLD is associated with the structural changes of gut flora.  
 
Although NAFLD is prevalent worldwide, there is no safe and effective drug for NAFLD. 
Several reports in Chinese medicine showed that some decoctions containing Rheum 
palmatum L. (RP) may be beneficial to improve fatty liver. The aim of the present study was 
to investigate the effect of RP on fatty liver induced by high fat diet (HFD) in rats and its 
underlying mechanisms. Aqueous RP extraction was orally administrated to HFD-fed rats for 
six weeks at low and high doses. Body weight, tissue weight, glucose tolerance, insulin 
tolerance, heptic morphology as well as liver triglyceride (TG) content were assessed. The 
effect of RP on the expression of lipogenic and lipolysis genes was measured by quantitative 
real-time PCR. Phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA 
carboxylase (ACC) were measured by Western Blotting analysis. Results showed that RP 
treatment at low dose significantly decreased liver weight, reduced liver TG content and 
improved glucose tolerance in HFD-fed rats. Consistently, RP attenuated excessive fat 
accumulation and down-regulated the expression levels of lipogenic genes in the rat liver. 















findings suggested that low dose of RP had beneficial effects in improving hepaticsteatosis, at 
least in part, by stimulation of AMPK activity, thus possesses therapeutic potential in treating 
hepatosteatosis.  
 
DNA microarray analysis is characterized by obtaining a large number of gene variables from 
a small number of observations. Cluster analysis is widely used to analyze DNA microarray 
data to make classification and diagnosis of disease. Because there are so many irrelevant and 
insignificant genes in a dataset, a feature selection approach must be employed in data 
analysis. The performance of cluster analysis of this high-throughput data depends on whether 
the feature selection approach chooses the most relevant genes associated with disease classes. 
Here we proposed a new method using multiple Orthogonal Partial Least Squares 
-Discriminant Analysis (mOPLS-DA) models and S-plots to select the most relevant genes to 
conduct three-class disease classification and prediction. We tested our method using Golub’s 
leukemia microarray data. For three classes with subtypes, we proposed hierarchical 
orthogonal partial least squares-discriminant analysis (OPLS-DA) models and S-plots to 
select features for two main classes and their subtypes. For three classes in parallel, we 
employed three OPLS-DA models and S-plots to choose marker genes for each class. The 
power of feature selection to classify and predict three-class disease was evaluated using 
cluster analysis. Further, the general performance of our method was tested using four public 
datasets and compared with those of four other feature selection methods. The results revealed 
that our method effectively selected the most relevant features for disease classification and 





















NAFLD, NonAlcoholic Fatty Liver Diseases 
NMR, Nuclear Magnetic Resonance 
UV, Unit Variance  
OPLS-DA, Orthogonal Partial Least Squares Discriminant Analysis 
PLS-DA, Partial Least Squares Discriminant Analysis 
TMOA, Trimethylamine N-oxide 
RP, Rheum palmatum L  
NCD, Normal Chow Diet 
HFD, High Fat Diet 
ACC1, Acetyl-Coenzyme A Carboxylase 1  
FAS, Fatty Acid Synthase 
SCD-1, Stearoyl-CoA Desaturase-1 
CPT-1, Carnitine PalmitoylTransferase-1 
ALT, ALanine Transaminase 
AST, ASpartate aminoTransferase 
LXR, Liver X Receptor 
SREBP1c, Sterol Regulatory Element-Binding Protein 1c 
ChREBP, CarboHydrate-Responsive Element-Binding Protein 
ACO, Acyl-CoA Oxidase 
ACOX1, Acyl-CoA Oxidase 1 
PPARα, Peroxisome Proliferator-Activated Receptor α 
mtGPAT, mitochondrial acyl-CoA:Glycerol-sn-3-Phosphate AcylTransferase 
DGAT1, diacylglycerol O -acyltransferase 1 
TG, triglyceride 
RT-PCR, Real-Time Polymerase Chain Reaction 
SCF, Subcutaneous Fat 















mOPLS-DA, Multiple Orthogonal Partial Least Squares Discriminant Analysis 
OSC, Orthogonal Signal Correction 
PCA, Principal Component Analysis 
CV-ANOVA, ANOVA of the cross-validated 
MC-SVM, Multi-Category Support Vector Machine 
OVR, One Versus Rest 
SVM, Support Vector Machine 
ALL-T, T-lineage Acute Lymphoblastic Leukemia  
ALL-B, B-lineage Acute Lymphoblastic Leukemia  
AML, Acute Myeloid Leukemia 
CA, Cluster Analysis 
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第一部分 利用基于 NMR 的代谢组学技术研究强化运动治疗非
酒精性脂肪肝的机制 
1.1 引言 





































NaH2PO4·2H2O 和 K2HPO4·3H2O 上海国药集团化学试剂有限公司生产。重
水（D2O，99%氘代）和 2，2，3，3-氘代三甲基硅烷丙酸钠（TSP）由美国 Cambridge 
Isotope Laboratories 公司生产。尿样磷酸缓冲液（NaH2PO4 / K2HPO4，1.5 M，pH 
7.4）用双蒸水配制（含 10% D2O，0.05%TSP）。5mm 核磁共振管生产于美国
NORELL 公司。 
1.2.2 试验方法 
    采用开放、随机、平行对照组方法。经筛选合格的受试者随机分配入运动干
预或对照组，运动干预组先进行一个月的运动量递增，达到并维持运动量在最大
耗氧量的 65-80% 6 个月，之后进行 6 月的常规运动治疗（每周 150 分钟的步行
干预）；对照组不改变原来的生活方式。整个过程中保持饮食不变。对所有受试
者均进行脂肪肝及相关疾病的定期宣教（前 2 个月每 2 周一次，之后的 5 个月每
月一次，最后 6 个月每 2 月一次）。 
1.2.3 样本量估计 
    根据以往的研究，计算得出运动干预组需要的人数为 29.2 人，总人数为 60
人。考虑到研究中的脱落因素及基因分析，招募受试者 120 人，每组 60 人。 
1.2.4 入选标准和排除标准 
入选标准 
    自愿参加并签署知情同意书；年龄在 40 岁到 65 岁；彩色 B 超检查符合脂
肪肝诊断；肥胖 (腰围：男＞90cm;女＞85cm)；任何代谢综合征的其他 2 个组分 


















    不愿意参与随机化；酒精性脂肪肝（饮酒量>）；有骨骼和肌肉疾病，不便
于运动；3 个月内接受过减肥治疗或采取其他减肥措施者；血压 SBP ≥ 
180mmHg,DBP ≥ 100mmHg；肝功能受损，定义谷丙转氨酶(ALAT) ≥ 2.5 倍的正
常上限 (复测一次)；肾功能受损，定义血肌酐≥ 135 μmol/L (≥ 1.5 mg/dL) （男
性），和 ≥ 110 μmol/L (≥ 1.3 mg/dL)（女性）；糖尿病；临床上显著的心血管疾
病，包括 6 个月内心肌梗死、心衰(NYHA 分级： III or IV)，踏车运动试验如果
ST-T 下降超过 0.10mv 排除；静息心电图 ST-T 下降超过 0.05mv 也排除 ；使用
可能干预运动效果评价的药物（如皮质醇、护肝药物等）。 
1.2.5 运动干预方式 
    强化运动阶段：跑步机。运动量：运动强度和时间在 4 周内逐步增加，最终
达到和维持在运动强度为最大心率的 65-80%（踏板运动测试），每次在跑步机上
运动持续 30 分钟，每周 5 天，运动时心率将根据每月的运动能力测试调整。运
动地点：运动干预在社区服务中心进行。 
常规运动阶段：步行：计步器定量，每周步行 150 分钟（每分钟 100-120 步）。
每周至少分 3 次。受试者每天记录计步器数据并每天清零。每周研究者汇总数据。
运动地点：不指定地点。 




    在强化运动治疗 6 个月后收集运动治疗组和对照组患者的晨尿(运动后约 18
个小时)，-80℃保存。 
1.2.7 样品配制 

















尿样的一维核磁共振波谱均在Varian Unity Inova 500MHz NMR (Varian, Inc.)
谱仪上采集。手动采样，使用1D tnnoesy序列，压水使用presat。压水参数：satpwr 




1.2.9 数据分析方法  
     对所有1H NMR 谱利用TOPSPIN2.0 软件进行相位和基线校正后，尿液用













































由于受到尿液 pH 值和尿中一些离子的影响，NMR 所采集谱峰会出现漂移。





















经过使用 NMR peak alignment 校正，可以看到峰型很整齐，如 Figure 2。 
 




1.3.2 强化运动 6 个月对尿代谢组的影响 
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